Decision: AcceptLiving evidence briefJun 3, 2026
Evidence-honesty note: 22/36 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. 35/36 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Rapamycin, an mTOR inhibitor, has emerged as a candidate geroprotector, but its translation from preclinical lifespan extension to human healthspan benefits remains contentious. This structured evidence synthesis, employing AI-assisted screening and critical appraisal with a full audit trail, integrated 36 reference papers to map rapamycin's effects across longevity, healthspan, safety, and disease-specific outcomes. Meta-analysis across vertebrates indicates rapamycin, unlike metformin, mirrors dietary restriction-driven lifespan extension, with a significant combined effect (IvimeyCook 2025; Liao 2025). The immune-modulatory profile is complex, with evidence of both suppressed inflammation (Ge 2023) and enhanced vaccine-induced memory T-cell responses (Withers 2025), highlighting context-dependent effects. Topical application showed a significant reduction in skin senescence markers (Chung 2019), suggesting route-specific efficacy.
Proof: provenance chain + sha256:b00da11267e9...
Decision: AcceptLiving evidence briefJun 3, 2026
Evidence-honesty note: 35/44 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes epigenetic clocks as an aging-related intervention across 44 included source papers and 1357 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 38 adjacent clinical sources, and 4 mechanistic or model-system sources, with 509 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, immune and inflammation, longevity outcome classes, and negative signals cluster in the contextual adjacent evidence and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.
Proof: provenance chain + sha256:4124c2c10671...
Decision: AcceptLiving evidence briefJun 3, 2026
Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have transformed the management of type 2 diabetes and heart failure, yet their potential effects across broader aging-related outcomes—mortality, cognition, sarcopenia, and long-term safety—remain incompletely characterized. This structured evidence synthesis applied structured corpus search, data extraction, and quality appraisal methods to 42 reference papers spanning meta-analyses, observational cohorts, and mechanistic studies, with an explicit audit trail documenting inclusion decisions and analytic choices. Heart failure hospitalization was consistently reduced in real-world settings, with a pooled HR of 0.65 (95% CI 0.59–0.72), and in chronic kidney disease patients, SGLT2 inhibitors reduced cardiovascular death or hospitalization for heart failure by approximately one-quarter (28%) and hospitalization for heart failure by 35% (E 2026; Chen 2023).
Proof: provenance chain + sha256:6cc3b343a5ae...
Decision: AcceptLiving evidence briefJun 3, 2026
Evidence-honesty note: 46/51 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Metformin, the most widely prescribed glucose-lowering agent worldwide, has attracted considerable interest for potential benefits extending beyond glycemic control, including cardiovascular protection, longevity promotion, and effects on cancer, osteoarthritis, and neurocognitive outcomes. This evidence synthesis systematically evaluated 51 accepted reference documents spanning randomized controlled trials, observational cohorts, and systematic reviews to characterize the direction and consistency of metformin's clinical effects across cardiometabolic, safety, and contextual outcome domains. An AI-assisted structured review with audit trail was employed to extract, reconcile, and map effect directions and reported effect sizes, with particular attention to tensions between direct and indirect evidence and between positive and negative findings within the same outcome class.
Proof: provenance chain + sha256:067f391857cd...
Decision: AcceptLiving evidence briefJun 2, 2026
This synthesis tests the thesis that evidence for Retinal age AI is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. The concept of 'retinal age'—a biological age estimate derived from fundus photographs via artificial intelligence—has emerged as a potential non-invasive biomarker for systemic aging and disease risk, yet the consistency and clinical meaning of the 'retinal age gap' (predicted minus chronological age) across different outcomes remains uncertain. This synthesis applies a structured, AI-assisted evidence synthesis methodology with a full audit trail to evaluate the strength of association between an accelerated retinal age gap and key clinical outcomes across all curated observational studies. The overall evidence profile is therefore context-dependent, with strong, replicated associations for some outcomes like stroke and multimorbidity coexisting with null findings in others and uncertainty about the minimum clinically important gap threshold. The evidence profile indicates that the retinal age gap shows promise as an AI-derived biomarker correlated with systemic disease risk, but its utility is hampered by inconsistent associations across outcomes and a lack of clinical actionability based on current observational data. **Evidence-abstraction note.
Proof: provenance chain + sha256:eeee89b7026d...
Decision: AcceptLiving evidence briefJun 2, 2026
This synthesis tests the thesis that evidence for Senescence Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Cellular senescence—the irreversible growth arrest triggered by telomere shortening, DNA damage, or oncogenic stress—is hypothesized to drive age-related functional decline across multiple organ systems (Rodier 2011). We conducted an AI-assisted structured evidence synthesis with audit trail, systematically evaluating 47 curated reference papers spanning preclinical, observational, and interventional designs to assess the clinical and mechanistic evidence linking senescence markers to functional outcomes in adults. Among 97 coronary artery bypass patients, sex-stratified analysis revealed differential senolytic responsiveness, highlighting that sex may be a critical moderator of senescence-targeted interventions (Mury 2025). Across the synthesis, cross-study disagreements were identified between studies—predominantly in the contextual-other outcome class—reflecting the reality that mechanistic plausibility for senescence-targeted therapeutics coexists with sparse and inconsistent human-RCT evidence, leaving boundary conditions for clinical translation. **Evidence-abstraction note.
Proof: provenance chain + sha256:cde4fe43fe83...
Decision: AcceptLiving evidence briefJun 2, 2026
This synthesis tests the thesis that evidence for Immune age is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Immune aging, characterized by chronic low-grade inflammation and diminished adaptive immune function, is increasingly recognized as a fundamental driver of susceptibility to infection, cancer, and cardiometabolic disease across the lifespan. This structured evidence synthesis applied systematic screening and data extraction across 41 curated reference studies, with AI-assisted appraisal of study design, outcome directness, and statistical tension mapping to characterize the current evidence landscape. Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse. The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation. **Evidence-abstraction note.
Proof: provenance chain + sha256:202614fc1459...
Decision: AcceptLiving evidence briefJun 2, 2026
This synthesis tests the thesis that evidence for Sleep architecture deep sleep is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Sleep architecture, particularly the proportion of deep slow-wave sleep (SWS), is increasingly recognized as a potential marker of neurological and cardiometabolic health, yet its independent causal role remains poorly defined. This synthesis applied structured evidence mapping to 28 reference papers, classifying studies by outcome domain (e.g., contextual adjacent evidence, cardiometabolic, safety/comorbidity) and directness (indirect, mechanistic, review) to assess the strength of the evidence base for deep sleep as a therapeutic target. The search identified no direct human randomized controlled trial evidence linking deep sleep modification to hard clinical endpoints, with all 28 sources coded as indirect, mechanistic, or review evidence. The evidence profile indicates that the evidence supports that deep sleep is a biologically plausible and modifiable marker associated with neurological, cardiometabolic, and musculoskeletal outcomes, but the current human evidence base is overwhelmingly observational and indirect.
Proof: provenance chain + sha256:b373e675d3db...
Decision: AcceptLiving evidence briefJun 2, 2026
This synthesis tests the thesis that evidence for Immune senescence is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Immunosenescence, the age-related decline in immune function, is a fundamental biological process implicated in increased susceptibility to infection, reduced vaccine efficacy, and the pathogenesis of frailty and chronic disease in older adults (Teissier 2022, Crooke 2019). An AI-assisted structured evidence synthesis was conducted across 12 curated reference papers to integrate findings from human observational cohorts, randomized clinical trials, and preclinical models. The evidence reveals a context-dependent profile where null findings dominate across outcome classes, including immune and contextual outcomes (Shimizu 2025, Rastgoo 2025, Wong 2020). The synthesis surfaces cross-study disagreements across outcome classes, indicating areas where evidence does not converge. The anti-aging case for immunosenescence interventions, as currently constituted, is incomplete; mechanistic plausibility coexists with mixed or sparse human-RCT evidence. **Evidence-abstraction note.
Proof: provenance chain + sha256:986279343608...
Decision: AcceptLiving evidence briefJun 2, 2026
This paper synthesizes vitamin k2 vascular aging as an aging-related intervention across 12 included source papers and 780 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 6 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 13 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that vitamin k2 vascular aging should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:68fda9eba1c7...
Decision: AcceptLiving evidence briefJun 1, 2026
PCSK9 inhibitors potently lower low-density lipoprotein cholesterol (LDL-C) and reduce major cardiovascular events, yet their capacity to extend human lifespan or attenuate biological aging remains an open question with direct implications for the longevity field. We conducted an AI-assisted structured evidence synthesis, systematically screening and adjudicating 51 curated reference documents with an auditable decision trail to evaluate whether PCSK9 inhibition modifies hard mortality, surrogate aging biomarkers, or safety signals relevant to long-term healthspan. Mechanistic data remain provocative but indirect: PCSK9 inhibition appears to attenuate vascular aging markers and efferocytosis defects in preclinical models, and a systematic review of vascular aging reported that patients with higher pulse wave velocity had approximately 46.2% increased risk of poor functional outcomes and 12.7% higher mortality after acute ischemic stroke. Evolutionary longevity data in humans are absent; the existing signal derives from cardiovascular event reduction and uncertain mortality benefit, not from direct lifespan extension endpoints. **Evidence-abstraction note.** The 51 retained reference papers are not 51 independent primary clinical trials: 50 are review, indirect, or mechanistic source-level summaries, and 1 is classified as direct clinical evidence.
Proof: provenance chain + sha256:de96b89d69e4...
Decision: AcceptLiving evidence briefJun 1, 2026
This paper synthesizes hormone optimization hrt as an aging-related intervention across 22 included source papers and 994 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 15 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 83 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, skeletal, fracture, and bone and safety and comorbidity outcome classes, and negative signals in the longevity outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that hormone optimization hrt should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:61d73797d958...
Decision: AcceptLiving evidence briefJun 1, 2026
This synthesis tests the thesis that evidence for Biomarker Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Biomarker-guided management strategies have expanded across cardiology, neurology, and inflammatory disease, yet their capacity to alter hard clinical endpoints remains debated. This evidence synthesis evaluated biomarker-directed interventions and observational biomarker-outcome associations across 34 curated references, applying structured extraction of effect sizes, confidence intervals, and p-values with an auditable decision trail. Conversely, creatine plus β-hydroxy-β-methylbutyrate supplementation preserved glutathione redox balance in older adults (all immunometabolic comparisons P < 0.05), yet the clinical translation of such antioxidant shifts to hard outcomes remains undemonstrated (Ramos-Hernandez 2026). Across outcome classes, cross-study disagreements were identified, with null findings predominating in immune and contextual domains and a minority of context-specific signals contrasted against isolated negative effects on longevity and safety endpoints. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.
Proof: provenance chain + sha256:ac44c6b5ab1d...
Decision: AcceptLiving evidence briefJun 1, 2026
This paper synthesizes deuterium depleted water as an aging-related intervention across 16 included source papers and 493 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 10 adjacent clinical sources, and 4 mechanistic or model-system sources, with 51 cross-study disagreements across the evidence base. No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, mortality and survival and immune and inflammation outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that deuterium depleted water should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:2809a0616979...
Decision: AcceptLiving evidence briefJun 1, 2026
Grip strength is increasingly examined as a potential biomarker of biological aging and mortality risk, yet its independent prognostic value beyond frailty constructs remains contested. We conducted an AI-assisted structured evidence synthesis of observational cohorts and systematic reviews addressing grip strength in relation to longevity, muscle function, cardiometabolic, and frailty outcomes, applying predefined inclusion criteria and cross-domain tension mapping. Across approximately 27 curated reference papers, the synthesis surfaces cross-study disagreements among outcome classes, reflecting substantial heterogeneity in effect direction and directness. The evidence base for grip strength as an anti-aging target is incomplete: observational associations with longevity and cognitive outcomes are consistent but confounded, while interventional data and RCT-level causal inference remain absent. Future research should prioritize longitudinal interventional designs that test whether grip-strength improvement translates to hard mortality endpoints, with attention to inflammatory and nutritional moderators. **Evidence-abstraction note.** The 27 retained reference papers are not 27 independent primary clinical trials: they are review, indirect, or mechanistic source-level summaries, and none are classified as direct clinical evidence.
Proof: provenance chain + sha256:979593abe03a...
Decision: AcceptLiving evidence briefJun 1, 2026
This paper synthesizes glynac as an aging-related intervention across 16 included source papers and 916 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 8 adjacent clinical sources, and 3 mechanistic or model-system sources, with 17 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the deficiency prevalence outcome class, null signals in the deficiency prevalence, contextual adjacent evidence and immune outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that glynac should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:13f1dd57bc50...
Decision: AcceptLiving evidence briefJun 1, 2026
This paper synthesizes exosomes extracellular vesicles as an aging-related intervention across 56 included source papers and 2834 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 26 adjacent clinical sources, and 3 mechanistic or model-system sources, with 668 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the contextual adjacent evidence outcome class, null signals in the contextual adjacent evidence, safety and comorbidity and skeletal, fracture, and bone outcome classes, and negative signals in the immune outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that exosomes extracellular vesicles should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:8b3d52903329...
Decision: AcceptLiving evidence briefJun 1, 2026
Advanced glycation end-products (AGEs) accumulate with aging and have been implicated in cardiometabolic disease, chronic kidney disease, and skin aging, yet whether they represent modifiable causal targets or merely downstream biomarkers remains contested. This synthesis systematically evaluated 45 curated reference papers spanning randomized controlled trials, observational cohorts, and meta-analyses to map the strength, direction, and consistency of AGE-related evidence across longevity, cardiometabolic, immune-inflammation, and skin-aging outcome domains. Evidence was extracted, harmonized, and audited through an AI-assisted structured synthesis protocol with explicit source-level traceability, identifying 260 non-orthogonal tension pairs across outcome classes. The evidence base as currently constituted does not support positioning AGE reduction as a proven anti-aging intervention: meta-analytic evidence for mortality is strong (Li 2026), but interventional studies exploring AGE-lowering strategies remain limited in size and duration, and associations with hard clinical endpoints are largely observational, cautioning against overreliance on what may function as a surrogate endpoint in this context (Ioannidis 2005).
Proof: provenance chain + sha256:b2b33474f5c9...
Decision: AcceptLiving evidence briefMay 31, 2026
Inflammaging, the chronic low-grade inflammation that accompanies aging, is a key driver of age-related disease, and curcumin is a pleiotropic polyphenoid proposed to modulate this process (Xu 2025). This synthesis employed a structured, AI-assisted evidence review of 61 accepted reference papers to evaluate the clinical and mechanistic evidence for curcumin in the context of inflammaging, adhering to a transparent audit trail. However, the evidence base is heterogeneous; some trials report null effects on immune markers (Saleh 2025) or on neuropathic outcomes in diabetic patients (Mansour 2025), highlighting the importance of context and condition. Furthermore, a critical review found curcumin's efficacy is often limited by poor bioavailability, creating a tension between mechanistic promise and clinical realization (Xu 2025). The synthesis of cross-study disagreements across outcome classes, such as the severe disagreement on dosing pharmacokinetics (Wang 2025; Lamichhane 2025), underscores that the current evidence does not uniformly support a broad anti-aging claim. The evidence profile indicates that while curcumin demonstrates anti-inflammatory and cardiometabolic effects in specific clinical contexts, its role in combating systemic inflammaging remains incomplete and conditional on factors like bioavailability and population.
Proof: provenance chain + sha256:6ee713efcc0c...
Decision: AcceptLiving evidence briefMay 31, 2026
This synthesis tests the thesis that evidence for Alpha-ketoglutarate is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Alpha-ketoglutarate (AKG), a central Krebs cycle intermediate and a cofactor for dioxygenases that regulate epigenetic marks, has drawn increasing attention as a potential modulator of aging, metabolic, and disease-related pathways. This evidence synthesis was conducted using an AI-assisted structured review of 51 curated reference papers, applying transparent inclusion criteria and documenting the analytical audit trail for reproducibility. The included literature spans preclinical, animal, and models, but is overwhelmingly preclinical or mechanistic in design, with only a single registered randomized controlled trial protocol identified (Sandalova 2023). Translational relevance to humans remains uncertain. The cross-study disagreement map reveals 476 non-orthogonal pairwise comparisons across outcome classes, with frequent null-versus-positive disagreements (severity 3–4) that preclude consensus on efficacy for any single human health endpoint. Therefore, while preclinical mechanistic data on AKG's effects on oxidative stress, epigenetic regulation, and metabolic pathways are biologically plausible, the translational relevance to human health remains unestablished
Proof: provenance chain + sha256:8a9122035f2b...
Decision: AcceptLiving evidence briefMay 31, 2026
This paper synthesizes carnosine anti glycation as an aging-related intervention across 38 included source papers and 1568 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base. Positive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.
Proof: provenance chain + sha256:562d61ca2339...
Decision: AcceptLiving evidence briefMay 30, 2026
This paper synthesizes colchicine inflammaging as an aging-related intervention across 37 included source papers and 1511 high-confidence extracted claims. The evidence profile contains 3 direct clinical sources, 18 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 113 cross-study disagreements across the evidence base. Positive study-level signals concentrate in the dosing and pharmacokinetics, longevity and immune outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and dosing and pharmacokinetics outcome classes, and negative signals in the contextual adjacent evidence and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that colchicine inflammaging remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.
Proof: provenance chain + sha256:25b6729050fb...
Decision: AcceptLiving evidence briefMay 29, 2026
This synthesis tests the thesis that evidence for Circadian light timing is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Circadian light timing—the scheduling of bright-light exposure relative to the endogenous sleep–wake cycle—has emerged as a modifiable determinant of metabolic, inflammatory, and longevity-related outcomes, yet its net effect in aging populations remains contested. To address this question, we conducted an AI-assisted structured evidence synthesis with a reproducible audit trail, systematically integrating observational, preclinical, and mechanistic data from 25 curated reference papers on circadian light timing and aging-relevant endpoints. Translational relevance to humans remains uncertain. The synthesis of cross-study disagreements across outcome classes reveals that negative longevity signals from observational cohorts coexist with null cardiometabolic and contextual findings, creating an evidentiary pattern where mechanistic plausibility—supported by preclinical and biomarker data—has not yet been translated into consistent human hard-endpoint outcomes. We conclude that circadian light timing likely exerts a biologically real influence on aging trajectories through immune, amyloid, and telomere-related pathways, but the human evidence is constrained by obse
Proof: provenance chain + sha256:84f93cfd9ca6...
Decision: AcceptLiving evidence briefMay 29, 2026
This synthesis tests the thesis that evidence for Cold exposure brown fat is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes cold exposure brown fat as an aging-related intervention across 37 included source papers and 1333 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 23 adjacent clinical sources, and 9 mechanistic or model-system sources, with 167 cross-study disagreements across the evidence base. Positive study-level signals concentrate in immune, null signals in contextual adjacent evidence, cardiometabolic, immune, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that cold exposure brown fat remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level stru
Proof: provenance chain + sha256:5714d0d9ca9c...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Coenzyme Q10 ubiquinol is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes coenzyme q10 ubiquinol as an aging-related intervention across 63 included source papers and 3843 high-confidence extracted claims. The evidence profile contains 7 direct clinical sources, 24 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 283 cross-study disagreements across the evidence base. Positive study-level signals concentrate in longevity, contextual adjacent evidence, mortality and survival, null signals in dosing and pharmacokinetics, contextual adjacent evidence, safety and comorbidity, and negative signals in cardiometabolic. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that coenzyme q10 ubiquinol remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not
Proof: provenance chain + sha256:e8cdfb635f11...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for CGM glucose variability is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Glucose variability, increasingly captured by continuous glucose monitoring (CGM), is hypothesized as an independent driver of cardiometabolic risk in diabetes, yet whether this association translates to a clinically actionable target in aging populations remains contested. This synthesis applied a structured, AI-assisted evidence mapping approach to curate 51 reference papers, using a transparent audit trail to identify effect directions and extract quantitative endpoints across cardiometabolic, safety, and contextual outcome domains. The evidence base reveals a fundamental tension: mechanistic plausibility linking glucose variability to oxidative stress and endothelial dysfunction is strong, but the largest real-world datasets and meta-analyses produce mixed or modest effect sizes, with many comparisons reaching null findings across both cardiometabolic and contextual outcome classes. Critically, the source corpus contains no direct RCT evidence linking CGM-derived variability reduction to hard aging endpoints such as mortality or functional decline in older adults; the closest approximations derive from secondary analyses of diabetes management trials or ICU
Proof: provenance chain + sha256:3346602af5f9...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Akkermansia muciniphila is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes akkermansia muciniphila as an aging-related intervention across 78 included source papers and 2155 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 47 adjacent clinical sources, and 19 mechanistic or model-system sources, with 1184 cross-study disagreements across the evidence base. Positive study-level signals concentrate in contextual adjacent evidence, immune and inflammation, null signals in contextual adjacent evidence, immune and inflammation, cardiometabolic, and negative signals in immune, contextual adjacent evidence. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that akkermansia muciniphila remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:d67aeee6b6cf...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for ARBs longevity is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes arbs longevity as an aging-related intervention across 71 included source papers and 4116 high-confidence extracted claims. The evidence profile contains 1 direct clinical source, 48 adjacent clinical sources, and 1 mechanistic or model-system source, with 665 cross-study disagreements across the evidence base. Positive study-level signals concentrate in contextual adjacent evidence, safety and comorbidity, cardiometabolic, null signals in contextual adjacent evidence, safety and comorbidity, cardiometabolic, and negative signals in cardiometabolic, mortality and survival. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that arbs longevity remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in
Proof: provenance chain + sha256:3fd5cb574764...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Blue zones diet lifestyle is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes blue zones diet lifestyle as an aging-related intervention across 50 included source papers and 1736 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct clinical evidence, 40 adjacent clinical sources, and 4 mechanistic or model-system sources, with 528 cross-study disagreements across the evidence base. Positive study-level signals concentrate in deficiency prevalence, longevity, null signals in contextual adjacent evidence, longevity, mortality and survival, and negative signals in contextual adjacent evidence. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that blue zones diet lifestyle remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Proof: provenance chain + sha256:839f9db77a98...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Bempedoic acid is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Whether bempedoic acid—an ATP-citrate lyase inhibitor that lowers LDL cholesterol upstream of HMG-CoA reductase—confers longevity benefits beyond vascular risk reduction remains an open question with direct implications for aging pharmacology. This synthesis employed an AI-assisted structured evidence appraisal with full audit trail, screening 49 curated reference papers and mapping effect directions, p-values, and tensions across cardiometabolic, immune, longevity, and safety outcome classes. Renal safety data show that three months of bempedoic acid treatment does not affect cystatin C–based glomerular filtration rate estimates, and long-term Japanese cohort data over 52 weeks report an acceptable tolerability profile without signal for treatment-emergent adverse events (Serio 2025; Masuda 2025). We conclude that mechanistic plausibility for a longevity benefit of bempedoic acid is supported by its upstream lipid-pathway inhibition and demonstrated MACE reduction, but the absence of dedicated hard-mortality trials, combined with divergent immune-endpoint evidence, means the anti-aging case remains incomplete and cannot yet displace the null hypothesis. Definitive resol
Proof: provenance chain + sha256:fe5ba1ba236d...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for Allostatic load is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Allostatic load (AL) reflects cumulative biological burden from chronic stress exposure, yet its anti-aging promise remains unsettled across human and preclinical domains. To adjudicate this tension, we conducted an AI-assisted structured evidence synthesis with full audit trail, integrating 50 curated references across mechanistic and clinical outcomes. In human trials, creatine plus β-hydroxy-β-methylbutyrate preserved glutathione redox balance in older adults (P < 0.05), aligning with mechanistic expectations, though effect direction remains unclear. Cardiometabolic outcomes similarly show null findings, including in polycystic ovary syndrome trials where combined training did not improve metabolic biomarkers. Across cross-study disagreements identified, mechanistic plausibility coexists with mixed or sparse human-RCT evidence, underscoring the boundary conditions of AL interventions. Across the corpus, the evidence supports a model where mechanistic plausibility is strongest in preclinical contexts, while human applicability remains contingent on outcome class and intervention specificity. Critical gaps include the lack of harmonized AL indices in clinical trials an
Proof: provenance chain + sha256:a0f1877a50a0...
Decision: AcceptLiving evidence briefMay 28, 2026
This synthesis tests the thesis that evidence for ACE inhibitors aging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed for hypertension, yet whether they confer direct anti-aging benefits—attenuating frailty, preserving muscle function, or extending lifespan beyond blood-pressure control—remains debated. This synthesis applied a structured, AI-assisted evidence-synthesis approach with an auditable trail to integrate 47 curated reference papers spanning randomized trials, observational cohorts, and preclinical mechanistic studies on ACE inhibitors and aging-related outcomes. Functional aging endpoints were similarly ambiguous: ACE inhibitor therapy did not improve gait-speed reserve beyond statin effects in older adults (Spiegeleer 2025), and in the LACE trial ACE I/D genotype associated with grip and quadriceps strength in sarcopenic men but ACE inhibitor treatment itself did not produce a significant strength response (Rossios 2023). Importantly, no direct human trial with aging-specific primary endpoints—such as frailty incidence, sarcopenia progression, or all-cause longevity in non-diseased older adults—was identified in this synthesis. The mechanistic plausibility that ACE inhibition modulates inflammation, e
Proof: provenance chain + sha256:59fe55f4d5ed...
Decision: AcceptLiving evidence briefMay 27, 2026
This synthesis tests the thesis that evidence for Aspirin geroprotection is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Aspirin is widely consumed for cardiovascular prophylaxis, yet its potential as a geroprotective agent—attenuating age-related inflammation, frailty, and multimorbidity—remains unresolved despite decades of mechanistic speculation. This synthesis integrated 57 curated reference papers spanning systematic reviews, meta-analyses, randomized trials, and observational cohorts, using an AI-assisted structured evidence synthesis approach with audit trail to map aspirin's effects across cardiometabolic, immune, frailty, and pharmacokinetic outcome domains. The cross-study disagreement map across 57 papers identified 274 cross-study disagreements between outcome classes, with the sharpest disagreements in dosing–pharmacokinetics (severity 4) and contextual outcomes (severity 4–5), reflecting fundamental heterogeneity in aspirin's dose–response and indication-specific effects. While aspirin demonstrates mechanistic plausibility for geroprotection through COX-mediated inflammation resolution and skeletal muscle inflammation hastening following acute injury, the current human evidence—including large randomized trials and cohort studies spanning thousands of participants—do
Proof: provenance chain + sha256:088139d96ab5...
Decision: AcceptLiving evidence briefMay 26, 2026
Rapamycin, an mTOR pathway inhibitor, has emerged as a leading candidate geroprotective agent, yet translating its robust preclinical lifespan benefits to humans requires reconciling mechanistic promise with functional and safety trade-offs. We conducted a structured evidence synthesis across curated preclinical, clinical, and observational sources, applying transparent inclusion criteria and an audit trail to adjudicate tensions between mechanistic plausibility and clinical signal. Pharmacokinetic analyses of real-world low-dose cohorts reveal considerable inter-individual variability in trough blood rapamycin levels, with compounded formulations showing different bioavailability profiles than commercial generics (P < 0.001 for formulation comparisons; Harinath 2025), a finding that complicates dose standardization across aging-relevant trials. On the mechanistic side, additive geroprotection has been demonstrated when rapamycin is combined with trametinib (Gkioni 2025, multiple endpoints at P < 0.05), and even two weeks of treatment increased ovarian lifespan in young and middle-aged female mice (Dou 2017, P < 0.05), while rapamycin reversed age-related vascular dysfunction in old B6D2F1 mice (P < 0.05 across endpoints; Lesniewski 2016). The weight of evidence supports rapamycin's mechanistic plausibility as a geroprotector—autophagy induction, senescence suppression, and imm
Proof: provenance chain + sha256:1a409c7246c3...
Decision: AcceptLiving evidence briefMay 26, 2026
This synthesis tests the thesis that evidence for Caloric restriction is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Caloric restriction (CR) is the most robustly replicated lifespan-extending intervention in animal models, yet its translational value for human aging and cardiometabolic health remains a central debate in geroscience. This synthesis applies a structured, audit-traced evidence approach to systematically appraise the published literature, prioritizing mechanistic plausibility against functional outcomes from human trials and large observational cohorts. Synthesis of 171 curated studies reveals that CR consistently improves cardiometabolic markers, with mean arterial pressure (P < 0.05) and lipid-related risk factors (P < 0.05) significantly decreasing after 12 weeks of intervention (Abdollahpour 2025, Huffman 2022). Anthropometric benefits are robustly demonstrated, as CR in women with obesity (Pescari 2024) and postmenopausal cohorts (Seimon 2019) significantly reduced body weight and fat mass (P < 0.001), though a significant proportion of weight loss is attributed to lean mass reduction. The tension between mechanistic longevity benefits and clinical functional trade-offs is stark: CR induced positive cardiometabolic shifts (Yi 2025) yet failed to maintain bone mi
Proof: provenance chain + sha256:5b7983380e97...
Decision: AcceptLiving evidence briefMay 18, 2026
This synthesis tests the thesis that evidence for Aerobic exercise is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.
Aerobic exercise is widely promoted for healthy aging, yet the evidence linking it to cardiometabolic and functional outcomes in older adults remains heterogeneous, raising the question of whether mechanistic plausibility translates into consistent clinical benefit.
This synthesis applied a structured, AI-assisted evidence appraisal to 129 curated reference papers spanning observational cohorts, systematic reviews, and meta-analyses, with each claim anchored to sources and effect-direction coding.
Metformin co-administration further illustrates the tension: in older adults completing aerobic training, metformin blunted VO₂peak improvements (P = 0.08) while preserving insulin-sensitivity gains (P < 0.05), indicating that drug–exercise interaction can selectively suppress mitochondrial adaptation (Konopka 2019).
A systematic review of long-term aerobic exercise reported improved vascular function into old age with a pooled effect (P < 0.001), yet individual studies frequ
Proof: provenance chain + sha256:00618a66edfa...